Aver Informatics is a Green Bay, WI based company that provides web-based collaborative data exploration software to the healthcare market that enables improved payment and clinical outcomes for healthcare payers and providers. Their software, Bloom, offers the unique ability to seamlessly link administrative claim data, clinical, pharmacy, encounter, or data from any other source, and equips everyday users with an intuitive visual interface to query massive data sets with ease. Aver actively contributes to healthcare reform by empowering organizations to tie cost and quality outcomes together that drive increased efficiency in healthcare delivery.
Cellectar, Inc closed a reverse merger with the publicly-owned Novelos Therapeutics , Inc. (NVLT) (Press Release April 11, 2011) and will assume the Novelos name. Headquarters will remain in Madison, WI. Novelos will continue to develop Cellectars three novel cancer-targeted compounds designated HOT, COLD and LIGHT which are selectively taken up and retained in cancer cells, including cancer stem cells.
Forward Health Group is a health care IT company founded in 2009 and based in Madison. Using their "Population Manager" platform, FHG harvests fragmented clinical and administrative health care data, stored in multiple and different IT platforms (many EPIC installed systems), and turns it into actionable information that can be used by physicians, administrators, and other subscribers to drive improved quality and lower costs in healthcare.
HarQen advances global communications by elevating voice from disposable media to easily accessible, usable content. By organizing conversations as they happen, HarQen enables users to find and share relevant voice content quickly. HarQen's award-winning Voice Management (VM) platform enhances the quality of communications by putting voice back into context and respecting it as a rich media asset. HarQen provides applications, white label solutions and an open API. Launched in 2007, HarQen is headquartered in Milwaukee, WI. Winner of Silvertip PwC Entrepreneurship Award in April 2011, honoring entrepreneurship and fast growing companies. Presented by The Angel Capital Association (ACA), the trade association of leading angel investment groups, in North America, in partnership with PricewaterhouseCoopers.
HealthMyne, Inc. is focused on delivering Quantitative Imaging Decision Support (QIDS) for Radiology and Oncology with expansion to other clinical specialties and non-US markets over time. The company's FDA-cleared software platform delivers image quantification, analytics and clinical information (EMR, RT, other data) into the primary workflow to drive clinical productivity; provides curated medical content, analysis and reporting to optimize clinical collaboration and enable precise patient management; and supports data mining for clinical, translational and commercial research.
Digital Intern - iVMD is a Madison-based company that seeks to improve patient care through standardization of best practices, reduce healthcare costs, and increase efficiency through their product, the Digital Intern. The first of several applications manages the care of organ donors, increases the number of organs successfully donated per donor, and cuts costs by decreasing physician billing time.
Madison Vaccines, Inc. (MVI) is a therapeutic vaccine development company. It is focused on treatments for early intervention in prostate cancer. In the US, there are 240,000 new cases of prostate cancer annually, 80,000 recurrences and 30,000 deaths. MVI has three assets: two vaccines and a companion diagnostic test. The vaccines will be targeted to patients who have been treated by surgery or radiation, and whose PSA levels begin to rise again indicating that cancer cells are still present.
Needls. has created an ad platform that allows businesses to automatically create, target, and optimize digital ads across Facebook, Twitter, Google, and Bing. Needls determines the perfect target audience for these ads by monitoring social media conversations through its proprietary purchase intent engine.
Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Companys Lead Candidate, QBI-139, is based on the Companys EVade Ribonuclease Technology, which consists of a human pancreatic enzyme, Ribonuclease I engineered to kill cancer cells. The EVade Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company is in the late pre-clinical stages of development of QBI-139 and is on target to file an Investigational New Drug Application by the end of 2007. This enables a Phase I human clinical trial to begin early in 2008.
SHINE Medical Technologies is dedicated to being the world leader in safe, clean, affordable production of medical tracers and cancer treatment elements. At SHINE, our highest priority is delivering a highly reliable, high-quality supply of the medical ingredients required by nearly 100,000 patients each day which are the backbone of over thirty medical procedures primarily used to detect and treat heart disease and cancer. By working around the clock, our goal is to ensure that medical tracers are there when patients need them most.
Silatronix is commercializing a new class of patented materials based on organosilicon (OS) compounds for use in energy storage devices, especially electrolytes for lithium-ion (Li-ion) batteries. Silatronix's compounds offer cell manufacturers the ability to create batteries that are safer (current generation Li-ion batteries readily combust - see recent Boeing 787 and Tesla battery fires), offer higher capacity (17-32% energy increase from increasing charge voltage from 4.2V to 4.4V or 4.6V), and a larger number of cycle lives before battery performance begins to degrade. Silatronix's OS material can be used in consumer electronics, the automotive industry, and in military applications.
Stemina Biomarker Discovery is a metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. Steminas cell based assays arise from the strategic convergence of two cutting edge technologies: human embryonic stem (hES) cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells, in response to drugs, injury or disease. Stemina opened its state-of-the-art facilities for hES cell culture and mass spectrometry in the UW Research Park in Madison Wisconsin on November 1, 2007.
TrackIF is an internet company focused on tracking and alerting consumers to pricing and other changes for items specifically selected by each user. TrackIf works similarly to Pinterest, but instead of simply "pinning" or sharing things, TrackIf has the ability to track and alert users if the merchandise they want drops in price, hits target prices, is back in stock or has special offers like free shipping. The company will make money in four distinct ways: affiliate marketing (commissions on purchases through TrackIf), targeted advertising/offers (Groupon-like offers to those who have expressed an interest in a specific product), business solutions (corporate subscription services) and market insights (future - market intelligence/analytics to help companies understand purchasing patterns).
Forte Research Systems, formerly PercipEnz Technologies, Inc. (name change announced WiSJ Sept. 29, 2010). Founded in 2000 and headquartered in Madison, Wisconsin, PercipEnz Technologies, Inc. develops and markets proprietary, enterprise-class clinical and translational research management systems for academic research organizations. By adopting a highly collaborative product development process, PercipEnz gathers, distills and fine-tunes the best ideas from world-class research institutions to deliver solutions addressing key operational challenges. Forte was purchased by Primus Capital in April 2015.
Hopster provides printable coupons on favorite household brands and allows the consumer to customize their experience. Using social influence, brand sharing and engagement, and purchase loyalty, the consumer can save more on everyday purchases, while providing the brand with valuable marketing data at the same time. Hopster was purchased by Inmar, Inc., a coupon processor.
Nerites Corporation was acquired January 31, 2011 by Kensey Nash Corp. of Exton, PA (Journal-Sentinel Online 1/31/11) for $20 million in cash. Nerites is developing novel medical devices based on technology derived from mussels from the ocean that are breakthroughs in providing new options for tissue repair and device coatings.
Performance Polymer Solutions Inc. (P2SI) was founded in 2002 to develop and commercialize high performance polymer products used primarily in aerospace and defense markets. Since its inception P2SI has successfully launched a variety of new products, including polyimides for advanced composites, fiber sizings, thermally stable adhesives, preceramic polymers, and carbon nanofiber treated yarns and textiles.
Stratatech Corporation is a regenerative medicine company focused on the commercialization of unique, proprietary skin substitute products for therapeutic and research uses. The company was founded in 2000 to commercialize an extraordinary discovery made at the University of Wisconsin-Madison. Stratatech was acquired by Mallinckrodt, a U.K. pharmaceutical firm, in 2016.
TermSync uses a Software-as-a-Service platform for an Accounts Receivable automation platform that helps companies improve customer relations, reduce processing costs, and get paid faster. TermSync was purchased by Esker, a document process automator.
Virent is an energy technology company that enables the renewable replacement of fossil fuels. Virents patented BioForming platform technology renewably produces liquid fuels, fuel gases, and many chemicals, all products most commonly made from fossil fuels. Based on the innovative Aqueous Phase Reforming (APR) pathway to biofuels and bioproducts, the BioForming process delivers more net energy and offers a scalable, cost-effective alternative to traditional biofuel production routes. The companys current research initiatives center on developing production capabilities for biogasoline, sugar-based biodiesel, hydrogen, and propylene glycol. Virent was acquired by Tesoro, one of the largest independent refiners and marketers of petroleum products in the United States, in September, 2016.